Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Deborah Tweddle.

Newcastle AuthorsTitleYearFull text
Dr Shelby Barnett
Dr Vickyanne Carruthers
Professor Deborah Tweddle
Professor Gareth Veal
Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance2022
Dr Lisa Allinson
Aaron Potts
Dr Matthew Bashton
Nermine Basta
Dr Al Gabriel
et al.
Loss of ALK hotspot mutations in relapsed neuroblastoma2022
Professor Deborah Tweddle
Neuroblastoma: a master of disguise and a challenge to cure2022
Dr Louise Hayes
Nermine Basta
Dr Colin Muirhead
Paul Gibson
Professor Deborah Tweddle
et al.
Temporal clustering of neuroblastic tumours in children and young adults from Ontario, Canada2022
Dr Shelby Barnett
Professor Deborah Tweddle
Professor Gareth Veal
Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients2022
Dr Nicholas Bown
Professor Deborah Tweddle
Frequency and Prognostic Impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High Risk Neuroblastoma trial (HRNBL-1)2021
Harriet Southgate
Dr Lindi Chen
Professor Nicola Curtin
Professor Deborah Tweddle
Increased replication stress determines ATR inhibitor sensitivity in neuroblastoma cells2021
Professor Gareth Veal
Professor Deborah Tweddle
Julie Errington
Pharmacokinetics and safety of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma: A randomized crossover clinical trial2021
Dr Nicholas Bown
Professor John Lunec
Professor Deborah Tweddle
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group2020
Harriet Southgate
Dr Lindi Chen
Professor Deborah Tweddle
Professor Nicola Curtin
ATR inhibition potentiates parp inhibitor cytotoxicity in high risk neuroblastoma cell lines by multiple mechanisms2020
Swathi Merugu
Dr Lindi Chen
Elizabeth Gavens
Hany Gabra
Dr Al Gabriel
et al.
Detection of circulating and disseminated neuroblastoma cells using the Imagestream Imaging Flow Cytometer for use as predictive and pharmacodynamic biomarkers2020
Hannah Smith
Harriet Southgate
Professor Deborah Tweddle
Professor Nicola Curtin
DNA damage checkpoint kinases in cancer2020
Harriet Southgate
Dr Lindi Chen
Professor Nicola Curtin
Professor Deborah Tweddle
Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma2020
Nermine Basta
Dr Richard McNally
Professor Deborah Tweddle
A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma2019
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Calum Kirk
Dr Katrina Wood
et al.
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma2019
Professor Gareth Veal
Julie Errington
Dr Leigh McDonald
Professor Deborah Tweddle
The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression2019
Dr Lindi Chen
Arman Esfandiari
Professor John Lunec
Professor Deborah Tweddle
Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours2018
Dr Jane Carr-Wilkinson
Dr Nilendran Prathalingam
Dr Deepali Pal
Dr Mohammad Moad
Dr Peter James
et al.
Differentiation of human embryonic stem cells to sympathetic neurons: A model for understanding neuroblastoma pathogenesis.2018
Professor Deborah Tweddle
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project2017
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Dr Katrina Wood
Professor Gareth Veal
et al.
In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma2017
Dr Al Gabriel
Dr Lindi Chen
Dr Sirintra Nakjang
Dr Daniel Williamson
Professor Deborah Tweddle
et al.
Combined Copy Number and Gene Expression Profiling in High Rick Neuroblastoma: A CCLG Pilot Biological Study2016
Hayley Bowyer
Professor Catherine Exley
Melissa Girling
Professor Deborah Tweddle
Delays to Diagnosis of Childhood Cancer: A Qualitative Study of Specialist Health Care Professionals' Views2016
Nermine Basta
Dr Gail Halliday
Richard Feltbower
Dr Nicholas Bown
Professor Andrew Pearson
et al.
Factors associated with recurrence and survival length following relapse in patients with neuroblastoma2016
Dr Lindi Chen
Angharad Humphreys
Dr Lisa Turnbull
Dr Nicholas Bown
Professor Deborah Tweddle
et al.
Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse2016
Angharad Humphreys
Dr Al Gabriel
Dr Nicholas Bown
Dr Lindi Chen
Dr David Jamieson
et al.
Imaging flow-cytometer based detection of ALK and MDM2 amplification in neuroblastoma cell lines2016
Professor Deborah Tweddle
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma2016
Alison Page
Dr Ghada Malik
Dr Andrew Hall
Professor Deborah Tweddle
The National Children's Cancer and Leukaemia Group Tissue Bank similar to Facilitating a Comprehensive Range of Paediatric Oncology Research2016
Professor Gareth Veal
Julie Errington
Dr James Hayden
Professor Deborah Tweddle
Carboplatin therapeutic monitoring in preterm and full-term neonates2015
Professor Gareth Veal
Julie Errington
Dr James Hayden
Professor Deborah Tweddle
Carboplatin therapeutic monitoring in preterm and full-term neonates2015
Dr Nicholas Bown
Professor John Lunec
Professor Deborah Tweddle
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification2015
Dr Lindi Chen
Professor Deborah Tweddle
Neuroblastoma and the p53 Pathway2015
Dr Lindi Chen
Professor Deborah Tweddle
Neuroblastoma and the p53 pathway 2015
Dr Lindi Chen
Professor Herbie Newell
Professor John Lunec
Professor Deborah Tweddle
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma2015
Laura Evans
Dr Lindi Chen
Dr Elaine Willmore
Professor Herbie Newell
Professor Deborah Tweddle
et al.
SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma2015
Andrew Shouksmith
Laura Evans
Professor Deborah Tweddle
Duncan Miller
Dr Elaine Willmore
et al.
Synthesis and Activity of Putative Small-​Molecule Inhibitors of the F-​Box Protein SKP22015
Dr Colin Muirhead
Professor Deborah Tweddle
Nermine Basta
Dr Richard McNally
Temporal clustering of neuroblastic tumours in children and young adults from Northern England2015
Professor Gareth Veal
Julie Errington
Professor Deborah Tweddle
Therapeutic drug monitoring approaches to the treatment of preterm and full-term neonates with cancer - A UK experience2015
Professor Deborah Tweddle
Adherence to UK Children's Cancer and Leukaemia Group Guidelines for the Management of Low and Intermediate Risk Neuroblastoma, 2011-20132014
Nermine Basta
Richard Feltbower
Dr Peter James
Professor Deborah Tweddle
Dr Richard McNally
et al.
Characteristics of UK patients with relapsed, intermediate risk unresectable, non-MYCN amplified neuroblastoma: a pilot study2014
Dr Emma Bell
Dr Frida Ponthan
Claire Whitworth
Professor Deborah Tweddle
Professor John Lunec
et al.
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib2014
Andrew Shouksmith
Laura Evans
Professor Roger Griffin
Professor Bernard Golding
Professor Herbie Newell
et al.
Design and synthesis of putative small-molecule inhibitors targeting the SCFSKP2 E3 ligase complex2014
Professor Deborah Tweddle
Professor Andrew Pearson
MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance2014
Dr Lindi Chen
Dr Yan Zhao
Dr Gail Halliday
Philip Berry
Professor Herbie Newell
et al.
Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma2014
Dr Colin Muirhead
Professor Deborah Tweddle
Dr Richard McNally
Temporal Clustering of Neuroblastoma in Children and Young People from Northern England2014
Nidal Boulos
Dr Michael Tilby
Professor Deborah Tweddle
Professor John Lunec
Identification and characterisation of STMN4 and ROBO2 gene involvement in neuroblastoma cell differentiation2013
Dr Lindi Chen
Professor Deborah Tweddle
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance2012
Nermine Basta
Dr Gail Halliday
Richard Feltbower
Dr Nicholas Bown
Professor Andrew Pearson
et al.
Factors associated with recurrence and length of survival following relapse in patients with neuroblastoma: a pilot study2012
Professor Deborah Tweddle
Professor John Lunec
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-632012
Dr Jonathan Fisher
Professor Deborah Tweddle
Neonatal neuroblastoma2012
Professor Deborah Tweddle
The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform2012
Dr Nicholas Bown
Professor John Lunec
Professor Deborah Tweddle
A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma2011
Dr Jane Carr-Wilkinson
Bojidar Goranov
Dr Chris Redfern
Dr Laura Gamble
Professor John Lunec
et al.
Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression2011
Dr Simon Bomken
Dr Barry Davies
Mike Cole
Dr Katrina Wood
Maritsa McDermott
et al.
Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival2011
Professor Deborah Tweddle
Dr Katia Mazzocco
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)2011
Rachel Daniel
Dr Agata Rozanska
Dr Evan Mulligan
Dr Yvette Drew
Huw Thomas
et al.
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-0146992010
Dr Jane Carr-Wilkinson
Kieran O'Toole
Angela Baker
Julian Board
Mike Cole
et al.
High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma2010
Dr Emma Bell
Dr Lindi Chen
Professor John Lunec
Professor Deborah Tweddle
MYCN oncoprotein targets and their therapeutic potential2010
Dr Lindi Chen
Dr Laura Gamble
Professor John Lunec
Professor Deborah Tweddle
p53 is a direct transcriptional target of MYCN in neuroblastoma2010
Dr Agata Rozanska
Dr Evan Mulligan
Huw Thomas
Deborah Castelbuono
Professor Deborah Tweddle
et al.
[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-0146992009
Dr Agata Rozanska
Huw Thomas
Dr Evan Mulligan
Dr Yvette Drew
Deborah Castelbuono
et al.
Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma2009
Dr Katrina Wood
Dr Michael Jackson
Dr Maria Lastowska
Dr Darroch Hall
Dr Helen Imrie
et al.
Histological profile of tumours from MYCN transgenic mice2008
Dr Emma Bell
Professor John Lunec
Professor Deborah Tweddle
Cell cycle regulation targets of MYCN identified by gene expression microarrays2007
Dr Jane Carr-Wilkinson
Dr Nicholas Bown
Marian Case
Dr Andrew Hall
Professor John Lunec
et al.
High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays2007
Dr Maria Lastowska
Dr Mauro Santibanez Koref
Ilka Wappler
Dr Heiko Peters
Dr Andrew Hall
et al.
Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data2007
Dr Lindi Chen
Professor Archibald Malcolm
Dr Katrina Wood
Mike Cole
Professor Andrew Pearson
et al.
p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma2007
Professor Steven Clifford
Rachel Daniel
Dr Agata Rozanska
Huw Thomas
Professor Alan Boddy
et al.
Preclinical evaluation of the POLY-ADP ribose polymerase 1 (PARP-1) inhibitor AG014699 in combination with topotecan and temozolomide for the treatment of medulloblastoma and neuroblastoma2007
Dr Simon Bomken
Dr Barry Davies
Dr Katrina Wood
Professor Deborah Tweddle
Tumour necrosis following chemotherapy in neuroblastoma correlates with MYC-N status but not survival2007
Dr Jane Carr-Wilkinson
Dr Emma Bell
Professor Andrew Pearson
Professor John Lunec
Professor Deborah Tweddle
et al.
Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse2006
Dr Simon Bomken
Dr Katrina Wood
Dr Michael Reid
Professor Deborah Tweddle
Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow2006
Dr Emma Bell
Dr Jane Carr-Wilkinson
Dr Xiaohong Lu
Professor Penny Lovat
Professor John Lunec
et al.
The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage2006
Dr Jayne Lamont
Professor Deborah Tweddle
Professor Andrew Pearson
Professor Steven Clifford
Professor David Ellison
et al.
A 7-year-old boy with midline cerebellar mass2005
Dr Tibor Nyari
Professor Andrew Pearson
Professor Deborah Tweddle
Julian Board
Large cell neuroblastoma: A distinct phenotype of neuroblastoma with aggressive clinical behavior2004
Professor Deborah Tweddle
MYCN amplification remains prognostically strong 20 years after its clinical debut2004
Professor Deborah Tweddle
Julian Board
Professor Andrew Pearson
Professor John Lunec
Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[131I]iodobenzylguanidine by neuroblastoma tumors2003
Dr Jane Carr-Wilkinson
Julian Board
Dr Katrina Wood
Professor Andrew Pearson
Professor John Lunec
et al.
Selection for p53 mutant cells by chemotherapy in high-risk neuroblastoma2003
Professor Deborah Tweddle
Professor Andrew Pearson
Professor John Lunec
The p53 pathway and its inactivation in neuroblastoma2003
Professor Deborah Tweddle
Professor Archibald Malcolm
Dr Nicholas Bown
Professor Andrew Pearson
Professor John Lunec
et al.
Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line2001
Professor Deborah Tweddle
Mike Cole
Professor Andrew Pearson
OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age2001
Professor Deborah Tweddle
Professor Archibald Malcolm
Mike Cole
Professor Andrew Pearson
Professor John Lunec
et al.
p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells2001
Professor Deborah Tweddle
Dr Kevin Windebank
Cyclosporin neurotoxicity after chemotherapy: Reply1999
Professor Deborah Tweddle
Dr Jennifer Kernahan
Cerebral candidiasis in a child 1 year after leukaemia1998
Professor Deborah Tweddle
Professor Andrew Pearson
Professor Archibald Malcolm
Professor John Lunec
Does TP53 function in neuroblastoma?1998
Professor Deborah Tweddle
Dr Stephen Pedler
Non-tuberculous mycobacterial infection in children with cancer1998
Professor Deborah Tweddle
Professor Archibald Malcolm
Dr Michael Reid
Mike Cole
Professor John Lunec
et al.
TP53 and related protein expression in primary and metastatic neuroblastoma1998
Professor Deborah Tweddle
Dr Kevin Windebank
Andrew Barrett
Central venous catheter use in UKCCSG oncology centres1997
Professor Deborah Tweddle
Dr Michael Reid
Aplastic anaemia in the northern region of England1996
Professor Deborah Tweddle
Electron microscopy and serological features of a patient with Q fever prosthetic valve endocarditis.1996
Professor Deborah Tweddle
Dementia presenting with sore eyes1992